Date: 2015-07-07
Type of information: Milestone
Compound: MP0112
Company: Molecular Partners (Switzerland) Allergan (Ireland)
Therapeutic area: Ophtalmological diseases
Type agreement: milestone
Action mechanism:
Disease: retinal diseases
Details: Molecular Partners has entered into a license agreement for MP0112, a phase II proprietary therapeutic DARPin® protein targeting VEGF under investigation for the treatment of retinal diseases, with Allergan. Under the agreement, Allergan obtains exclusive global rights for MP0112 for ophthalmic indications. The parties will work together during phase IIb development and, Allergan will be responsible for phase III development and commercialization activities. Data on MP0112 from two separate phase I/IIa trials in wet age-related macular degeneration (wetAMD) and diabetic macular edema (DME) were presented at the meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Fort Lauderdale, FL earlier this week (May 1-5,2011). The studies showed that MP0112 is well tolerated and has a potentially long lasting effect on vision gain after a single injection.
Financial terms: Molecular Partners will receive an up-front payment of $45 million and is further entitled to receive additional payments of up to an aggregate of $375 million upon meeting certain development, regulatory and sales milestones. In addition, Molecular Partners will receive tiered double-digit royalties on any future sales of MP0112.
Latest news: * On July 7, 2015, Molecular Partners announced that its partner Allergan has initiated phase III clinical trials with abicipar pegol (abicipar) for the treatment of wet age-related macular degeneration (wet AMD). The event triggered a clinical milestone payment to Molecular Partners of $ 15 million.
